recombinant stem cell factor  (R&D Systems)

Journal: Metabolic engineering

Article Title: Multiplex genome editing of mammalian cells for producing recombinant heparin.

doi: 10.1016/j.ymben.2022.01.002

Figure Lengend Snippet: Fig. 3. Mast cells as a model for engineering recombinant heparin. a) BMDC were differentiated into mast cells over three weeks. HS was purified from precursor and differentiated cells and sulfate content was determined by LC/MS on the heparin lyase digested disaccharides. Analysis was performed once per cell type. Corre sponding disaccharide composition data is shown in Fig. S5. b) RNA-Seq analysis was used to quantify HS biosynthetic enzyme transcripts from cultured BMDC, differentiated mast cells and MST cells. The position of each of these genes in the biosynthetic pathway is shown in Fig. 1a. (n = 3 independent samples each cell type).

Article Snippet: Recombinant murine IL-3 (1 ng/mL; R&D Systems) and recombinant murine stem cell factor (SCF; 20 ng/mL; R&D Systems), both shown to support the in vitro growth and differentiation of the mast cell precursor, were also included (Wang et al., 2012).

Techniques: Recombinant, Purification, Liquid Chromatography with Mass Spectroscopy, RNA Sequencing, Cell Culture